Zepbound vs. Jardiance

See how Zepbound and Jardiance compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Zepbound is a weekly injection approved for chronic weight management and moderate-to-severe obstructive sleep apnea, while Jardiance is a daily pill approved for type 2 diabetes, heart failure, and chronic kidney disease.

  • Zepbound produces substantially more weight loss than Jardiance, but it costs roughly $1,050 to $1,100 a month compared with $350 to $620 for Jardiance.

  • These drugs work through entirely different mechanisms and treat different conditions, so some people with both obesity and type 2 diabetes end up taking both under a doctor's care.

Zepbound vs. Jardiance Drug Summary

Zepbound

Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist given as a once-weekly injection. It is FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity. Dosing starts low and increases every four weeks to a maintenance dose.

Jardiance

Jardiance (empagliflozin) is an SGLT2 inhibitor taken as a once-daily oral tablet. It is FDA-approved to help control blood sugar in type 2 diabetes, reduce cardiovascular death in adults with diabetes or heart failure, and slow chronic kidney disease progression. Most patients start on one daily dose that may be increased if more control is needed.

Zepbound vs. Jardiance Side Effects

Zepbound

Most common
Nausea (up to 29%)
Diarrhea (up to 23%)
Constipation (up to 17%)
Vomiting (up to 13%)

Jardiance

Most common
Hypoglycemia (up to 41.3% with insulin/sulfonylurea)
Volume depletion related reactions (up to 11.4%)
Urinary tract infection (up to 9.3%)
Female genital mycotic infection (up to 5.4%)

Zepbound vs. Jardiance Dosage

Zepbound

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 2.5 mg once weekly Weeks 1-4
Maximum dose 15 mg once weekly Week 21 onward
Dose changes 5 increases Every 4 weeks

Jardiance

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg once daily At the start
Maximum dose 25 mg once daily If needed
Dose changes 1 increase As tolerated

Zepbound vs. Jardiance Indications

Zepbound

Zepbound is approved for long-term weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity, always alongside diet and exercise changes. It is not FDA-approved to treat type 2 diabetes, even though its active ingredient tirzepatide is also sold separately as Mounjaro for that purpose.

  • Chronic weight management in adults with obesity

  • Weight management in overweight adults with a related condition

  • Moderate-to-severe obstructive sleep apnea with obesity

  • Used with reduced-calorie diet and increased exercise

Jardiance

Jardiance treats type 2 diabetes and, separately, reduces cardiovascular death risk in adults who have heart failure or existing cardiovascular disease. It is also approved to slow the progression of chronic kidney disease, regardless of diabetes status.

  • Blood sugar control in type 2 diabetes (age 10+)

  • Reduce cardiovascular death risk with heart disease

  • Reduce death and hospitalization risk in heart failure

  • Slow chronic kidney disease progression

Zepbound vs. Jardiance Pros and Cons

Zepbound

Zepbound produces substantial weight loss and is the only medication also approved for obstructive sleep apnea. It requires a weekly injection and is often not covered by insurance when prescribed for weight loss alone.

Pros

  • Also FDA-approved for obstructive sleep apnea

  • Produces greater average weight loss than oral options

  • Dual GIP/GLP-1 action may curb appetite more strongly

  • Once-weekly dosing schedule

Cons

  • Common GI side effects like nausea and diarrhea

  • Requires self-injection rather than a pill

  • Roughly $1,050 to $1,100 a month without insurance, before savings programs

  • Not approved to directly treat diabetes

Jardiance

Jardiance has over a decade of real-world safety data and covers several serious conditions beyond diabetes, including heart failure and kidney disease. Its weight loss effect is modest compared with Zepbound.

Pros

  • Once-daily oral tablet, no injections needed

  • Also approved for heart failure and kidney disease

  • Long track record since its 2014 approval

  • Roughly $350 to $620 a month before insurance, less than Zepbound

Cons

  • Only modest weight loss, not a primary use

  • Raises risk of genital and urinary infections

  • Rare risk of diabetic ketoacidosis

  • Rare risk of Fournier's gangrene

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.